Lindbrook Capital, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Lindbrook Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$20.27 - $42.44 $9,243 - $19,352	456 Added 506.67%	546 $23,000
Q3 2023 Oct 25, 2023	BUY	$20.26 - $31.91 $303 - $478	15 Added 20.0%	90 $1,000
Q2 2023 Jul 28, 2023	BUY	$23.9 - $35.38 $1,792 - $2,653	75 New	75 $2,000
Q1 2022 Apr 21, 2022	SELL	$23.5 - $35.38 $3,055 - $4,599	-130 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$29.21 - $44.64 $2,336 - $3,571	80 Added 160.0%	130 $4,000
Q3 2021 Nov 05, 2021	BUY	$21.26 - $38.85 $1,063 - $1,942	50 New	50 $1,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.